ACCESS Newswire
23 Nov 2021, 11:35 GMT+10
EATONTOWN, NJ / ACCESSWIRE / November 23, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for Regenerative and Personalized Medicine announced today that it has added John 'Jay' Schwartz, PhD to its Scientific and Medical Advisory Board.
Dr. Schwartz, who holds a PhD in biochemistry and molecular biology, has served as an academic researcher at Harvard and MIT for over 10 years. He is an accomplished life sciences entrepreneur, business mentor, consultant, and investor with a demonstrated track record of identifying and driving commercially-viable, early-stage companies from initial bench conceptualization and funding to clinical development and exit. Dr. Schwartz's 30+ years of entrepreneurship spans technical development and commercialization of drugs, medical devices, combination products, and diagnostics; regulatory approval, Orphan Drug/accelerated approval, clinical reimbursement, as well as intellectual property strategies.
Dr. Schwartz's business development experience includes negotiating and closing multiple collaborative development, supply, and license agreements. Most recently, he led AcuityBio Corporation to a successful acquisition by Cook Biotech. Over his career, he has led and advised multiple companies to successful exits via acquisition in transactions ranging from $35 to $500 million. Over the past 21 years, through his connection with MIT Venture Mentoring Service and as an adjunct instructor with National Science Foundation's ICorps program he has mentored many life science and technology companies.
John Arnone, CEO of American CryoStem Corporation, commented, 'The addition of Dr. Schwartz, a seasoned biotechnology executive, and successful entrepreneur, will accelerate the next evolution of the Company's strategy leading to multiple successful Biologic License Applications. Dr. Schwartz will bring critical expertise and proven executive leadership to our mission of developing a world-class pipeline portfolio.'
Dr. Schwartz stated, ‘I am very impressed by American CryoStem's robust, scalable, and repeatable stem cell technology platform that overcomes the historical technical and business model constraints that has hampered progress in this sector. I am proud to join my academic and clinical colleagues on this Advisory Board and look forward to the work ahead in building a pipeline of high value for medicine, stem cell and regenerative medicine therapies to transform the lives of patients suffering from serious illnesses.'
For further information please visit: www.americancryostem.com, send email to: [email protected] or contact the Company directly at 732-747-1007.
About American CryoStem Corporation: (CRYO), founded in 2008, is a clinical-stage biotechnology Company, developing and delivering autologous mesenchymal stem cell (MSC) therapies leveraging its 'mCMC' mesenchymal Chemistry, Manufacturing, and Controls patented cellular platform. The Platform supports a growing pipeline of biologic therapies, products and processes, collaborative development opportunities, clinical and international licensing opportunities. The Company's platform provides patients the opportunity for a single adipose-tissue (fat) harvest to be processed, stored and ultimately used for cosmetic fat transfer purposes and/or for processing to MSC's. The platform is configured to produce large quantities of genetically matched mesenchymal stem cells (ATCELLTM) for future individual or successive multiple treatments as needed, 'on demand'.The Company has strategically positioned its cellular therapy product pipeline to; attract collaborative partners, accelerate creation of new treatment applications, and improve manufacturing processes and testing methods. Each new therapy indication is designed to result in additional intellectual property and targeted commercial products to ultimately produce significant future revenue. CRYO is targeting untreatable and incurable neurologic diseases, disorders, and conditions that have a large unmet medical need and US FDA Orphan drug designation. The Company operates a cGMP compliant, FDA registered laboratory, located in Monmouth Junction, New Jersey, USA, and licensed laboratory operations in Hong Kong, China and Thailand.
SOURCE: American CryoStem Corporation
Get a daily dose of Hawaii Telegraph news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Hawaii Telegraph.
More InformationMADRID, Spain: Liverpool footballer Diogo Jota and his younger brother, André Silva, have died in a car accident in Spain. Spanish...
LONDON, U.K.: An unrelenting heatwave sweeping across Europe has pushed early summer temperatures to historic highs, triggering deadly...
President Donald Trump's plans to build a space-based Golden Dome missile defense shield have drawn immediate criticism from China,...
NEW YORK CITY, New York: Paramount has agreed to pay US$16 million to settle a lawsuit brought by U.S. President Donald Trump over...
LONDON, U.K.: British Prime Minister Keir Starmer won a vote in Parliament this week to move ahead with changes to the country's welfare...
WASHINGTON, D.C.: President Donald Trump will meet Israeli Prime Minister Benjamin Netanyahu at the White House on Monday. President...
FRANKLIN, Tennessee: Hundreds of thousands of Nissan and Infiniti vehicles are being recalled across the United States due to a potential...
REDMOND, Washington: Microsoft is the latest tech giant to announce significant job cuts, as the financial strain of building next-generation...
LONDON UK - U.S. stock markets were closed on Friday for Independence Day. Global Forex Markets Wrap Up Friday with Greeback Comeback...
SANTA CLARA, California: Nvidia came within a whisker of making financial history on July 3, briefly surpassing Apple's all-time market...
SACRAMENTO, California: California's multibillion-dollar farms are facing a growing crisis—not from drought or pests, but from a sudden...
WASHINGTON, D.C.: President Donald Trump says the United States could soon reach a trade deal with India. He believes this deal would...